首页> 外文OA文献 >Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

【2h】

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

机译：与苯甲酰胺的随机期III试验中的健康有关的生活质量（HRQL），具有标准的转移性，激素敏感前列腺癌（MHSPC）：ENZAMET（ANZUP 1304），ANZUP-LED，国际，共同手术团体试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M.R. Stockler; A.J. Martin; H. Dhillon; I.D. Davis; K.N. Chi; S. Chowdhury; L.G. Horvath; N.J. Lawrence; G.M. Marx; J Mc Caffrey; R. McDermott; S.A. North; F. Parnis; D.W. Pook; M.N. Reaume; S.K. Sandhu; T.H. Tan; A. Thomson; R. Zielinski; C.J. Sweeney;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial [J] . Loriot Yohann, Miller Kurt, Sternberg Cora N., The lancet oncology . 2015,第5期

机译：恩杂鲁胺对无症状和极少症状，未接受化疗的转移性去势抵抗性前列腺癌（PREVAIL）患者的健康相关生活质量，疼痛和骨骼相关事件的影响：一项随机的3期临床研究的结果
2. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial [J] . Khalaf Daniel J., Sunderland Katherine, Eigl Bernhard J., European urology . 2019,第6期

机译：与抗转移性阉割前列腺癌患者的Abiraaterone Plus Veinnisone对indnalutamide的健康相关生活质量：II期随机试验的结果
3. Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer [J] . Carol M. Moinpour, Gary W. Donaldson, Astra M. Liepa, Quality of Life Research . 2012,第5期

机译：在具有大量不可忽视的缺失数据和异质性反应的临床试验中评估与健康相关的生活质量治疗效果：吉西他滨联合紫杉醇与紫杉醇单药治疗转移性乳腺癌患者的III期随机试验结果
4. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours [O] . Nicola J. Lawrence, Howard Chan, Guy Toner, 2018

机译：P3BEP试验的方案（ANZUP 1302）：一项针对中度和低度转移性生殖细胞肿瘤的成年和儿科男性和女性患者的加速与标准BEP化疗的国际随机3期试验
5. Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study) [O] . O. Caffo, E. Palesandro, F. Nole, 2019

机译：更新的多中心期II型随机试验的多元丙二酸（D）加苯甲酰胺（e）与多元紫杉醇（d）作为患者（PTS）的多元化化疗，具有转移性阉割的前列腺癌（MCRPC）（Cheiron研究）

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

著录项

相似文献

相关主题

期刊订阅